
PDSB
PDS Biotechnology Corp
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.210
Open
1.210
VWAP
1.18
Vol
165.72K
Mkt Cap
55.31M
Low
1.160
Amount
195.94K
EV/EBITDA(TTM)
--
Total Shares
36.68M
EV
36.12M
EV/OCF(TTM)
--
P/S(TTM)
--
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.220
+4.76%
--
--
-0.223
-22.99%
--
--
-0.233
+1.45%
Estimates Revision
The market is revising No Change the revenue expectations for PDS Biotechnology Corporation (PDSB) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -6.00%.
EPS Estimates for FY2025
Revise Upward

+3.75%
In Past 3 Month
Stock Price
Go Down

-6.00%
In Past 3 Month
3 Analyst Rating

538.30% Upside
Wall Street analysts forecast PDSB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PDSB is 7.50 USD with a low forecast of 4.50 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

538.30% Upside
Current: 1.175

Low
4.50
Averages
7.50
High
13.00

538.30% Upside
Current: 1.175

Low
4.50
Averages
7.50
High
13.00
B. Riley
Buy
downgrade
$7 -> $5
2025-04-25
Reason
B. Riley
Price Target
$7 -> $5
2025-04-25
downgrade
Buy
Reason
B. Riley lowered the firm's price target on PDS Biotechnology to $5 from $7 and keeps a Buy rating on the shares. The firm cites PDS01 f antibody drug conjugate triplet revenue contribution push out given the company's heightened focus on securing Versamune HPV doublet path to market for the target cut.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$21 → $13
2025-03-27
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21 → $13
2025-03-27
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2025-03-13
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21
2025-03-13
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2025-03-07
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21
2025-03-07
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2025-02-24
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21
2025-02-24
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2024-12-18
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21
2024-12-18
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for PDS Biotechnology Corp (PDSB.O) is -1.42, compared to its 5-year average forward P/E of -5.01. For a more detailed relative valuation and DCF analysis to assess PDS Biotechnology Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-5.01
Current PE
-1.42
Overvalued PE
-0.77
Undervalued PE
-9.24
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.62
Current EV/EBITDA
-0.68
Overvalued EV/EBITDA
0.11
Undervalued EV/EBITDA
-7.35
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
86.16
Current PS
0.00
Overvalued PS
462.23
Undervalued PS
-289.90
Financials
Annual
Quarterly
FY2025Q1
YoY :
-9.82%
-9.11M
Operating Profit
FY2025Q1
YoY :
-19.94%
-8.49M
Net Income after Tax
FY2025Q1
YoY :
-30.00%
-0.21
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
50.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
50.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PDSB News & Events
Events Timeline
2025-07-10 (ET)
2025-07-10
08:07:34
PDS Biotech completes patient recruitment in Stage 1 colorectal cancer trial

2025-06-02 (ET)
2025-06-02
08:16:44
PDS Biotechnology unveils updated positive data from VERSATILE-002 trial

2025-05-14 (ET)
2025-05-14
07:38:13
PDS Biotechnology reports Q1 EPS (21c), consensus (25c)

Sign Up For More Events
Sign Up For More Events
News
8.5
05-27SeekingAlphaPDS Biotechnology files to sell 9.82M shares of common stock for holders
9.0
05-22NewsfilterPDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
9.0
05-22NASDAQ.COMPDS Biotechnology Reports Promising Overall Survival Data for Versamune® HPV Combined with Pembrolizumab in HPV16-Positive Head and Neck Cancer
Sign Up For More News
People Also Watch

STTK
Shattuck Labs Inc
0.868
USD
-0.12%

RPID
Rapid Micro Biosystems Inc
4.300
USD
-0.92%

EMCG
Embrace Change Acquisition Corp
12.050
USD
0.00%

GEG
Great Elm Group Inc
2.140
USD
0.00%

SWVL
Swvl Holdings Corp
4.080
USD
0.00%

XPL
Solitario Resources Corp
0.732
USD
+0.83%

HYMC
Hycroft Mining Holding Corporation
3.561
USD
-3.50%

NTZ
Natuzzi SpA
2.850
USD
0.00%

RFAC
RF Acquisition Corp
2.780
USD
-218.52%

CLRC
ClimateRock
12.000
USD
-1.42%
FAQ

What is PDS Biotechnology Corp (PDSB) stock price today?
The current price of PDSB is 1.175 USD — it has decreased -2.89 % in the last trading day.

What is PDS Biotechnology Corp (PDSB)'s business?

What is the price predicton of PDSB Stock?

What is PDS Biotechnology Corp (PDSB)'s revenue for the last quarter?

What is PDS Biotechnology Corp (PDSB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for PDS Biotechnology Corp (PDSB)'s fundamentals?

How many employees does PDS Biotechnology Corp (PDSB). have?
